Medifoxamine: oral tolerance and pharmacokinetic
study in healthy human volunteers
by
Saleh S, Johnston A, Turner P
Clinical Pharmacology,
St. Bartholomew's Hospital, London, UK.
Eur J Clin Pharmacol 1990; 39(2):169-71

ABSTRACT

Medifoxamine is a monoamine reuptake inhibiting antidepressant drug. We have investigated its pharmacokinetics in normal healthy volunteers. After an overnight fast, ascending doses of 200, 500, 750 and 1000 mg of medifoxamine were taken orally. Plasma samples were analysed using a specific HPLC method. Medifoxamine was well tolerated and exhibited a first order linear pharmacokinetic profile. It underwent rapid absorption and peak plasma concentrations were achieved about 1.0 h after administration. Thereafter the elimination profile was biphasic with a mean terminal half life less than 3 hours. We found a linear relationship (r = 0.80) between administered dose and AUC values for the four doses. High values were obtained for the apparent volumes of distribution and the plasma clearance.

5-HT1
5-HT2
5-HT3
Serotonin
Dopamine
Venlafaxine
Noradrenaline
Medifoxamine v imipramine

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family